Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment
J. Waters(King's College Hospital), Matthew Streetly(King's College - North Carolina), Ana Duran Maestre(Lewisham and Greenwich NHS Trust), Douglas Gunning(King's College Hospital), Hannah Patrick(Lewisham and Greenwich NHS Trust), Kirsty Cuthill, Sophie Deppe(King's College Hospital), Stella Bowcock(King's College Hospital), Alice Mason(King's College Hospital), Maj Kazmi(King's College Hospital), Reuben Benjamin(King's College London), Carmel Rice(King's College Hospital NHS Foundation Trust), Grace Milner
Cited by 1
Related Papers
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
|Blood|2023|330
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315